USFDA inspection: Alembic Pharma gets 2 observations for Karkhadi facility

Published On 2023-03-25 05:45 GMT   |   Update On 2023-03-25 05:45 GMT
Advertisement

Vadodara: Drugmaker, Alembic Pharmaceuticals, has announced that the US Food and Drug Administration (USFDA) has issued a Form 483 with two minor procedural observations following an inspection at the company's Injectable and Ophthalmic Facility (F-3) located at Karkhadi, Gujarat.

 An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. 

Advertisement

The inspection was conducted from 16th March, 2023 to 24th March, 2023.

"We would like to inform that the USFDA has conducted an inspection at Alembic Pharmaceuticals’ Injectable and Ophthalmic Facility (F-3) located at Karkhadi from 16th March, 2023 to 24th March, 2023," the company stated in a BSE filing.
"None of the observations are related to data integrity and management believes that they are addressable," the company 
further stated.
"The Company is preparing the response to the observations, which will be submitted to the USFDA within stipulated period. The Company is committed to maintain the highest quality standards and compliance at all times," Alembic added.
Medical Dialogues team had earlier reported that the Company had received an Establishment Inspection Report (EIR) from the USFDA for the inspection carried out at the company's Injectable Facility (F-3) at Karkhadi from 18th August, 2022 to 30th August, 2022.

Headquartered in Vadodara, Gujarat, Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. The company was founded in 1907. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic has a cumulative total of 183 ANDA approvals (160 final approvals and 23 tentative approvals) from USFDA.

Read also: Alembic Pharma successfully completes USFDA inspection for Derma Facility at Karakhadi

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News